Lipid & Vaccine Delivery Solutions

End-to-End Vaccine Delivery Platforms for Efficient Development

We provide a diverse portfolio of advanced delivery technologies tailored to distinct immunological targets. From ionizable lipid nanoparticles (LNPs) optimized for mRNA stability to novel adjuvant systems for protein subunits, our platforms support comprehensive research into both systemic and mucosal immunity.

mRNA-LNP Research Platforms

• Optimized Systems: 4-component LNP formulations (ionizable lipid, cholesterol, PEG-lipid, helper lipid) designed for high encapsulation efficiency.
• Thermostability Research: Development of lyophilized (freeze-dried) LNPs to investigate stability improvements for cold-chain logistics.
• Self-Amplifying RNA (saRNA): Specialized carrier designs capable of accommodating larger RNA payloads for research applications.
• Cellular Targeting: Surface modification research (e.g., Mannose) to study uptake by antigen-presenting cells (APCs).

Adjuvant System Development

• Lipid-Based Adjuvants: Custom synthesis of MPLA (Monophosphoryl Lipid A) analogs and glycolipid immunomodulators.
• Combination Systems: Co-encapsulation of antigens with TLR7/8 or TLR9 agonists to investigate innate immune activation pathways.
• Saponin-Lipid Nanoparticles: Structures mimicking ISCOMs for evaluating humoral and cellular immunity in animal models.
• Depot Effect Engineering: Tuning lipid composition to study antigen retention at the injection site.

Liposomal Protein Vaccine Carriers

• Subunit Delivery: Cationic liposomes (e.g., DOTAP-based) for electrostatic adsorption of anionic protein antigens.
• Biomimetic Carriers: Research into reconstituted viral envelopes (Virosomes) to mimic native virus structures.
• Cytosolic Delivery: pH-sensitive liposomes designed to facilitate endosomal escape and MHC Class I presentation research.
• Hapten-Lipid Conjugates: Linkage of small molecule antigens to lipid carriers to assess immunogenicity.

Mucosal Delivery Research

• Intranasal & Oral Systems: Investigation of mucoadhesive lipid-polymer hybrids (e.g., Chitosan-coated LNPs) for mucosal barrier penetration.
• IgA Induction Studies: Formulations optimized to evaluate Secretory IgA (sIgA) production in preclinical models.
• Mucus Stability: PEGylation strategies to test particle stability in mucin-rich environments.
• Inhalable Formulations: Development of spray-dried lipid powders for needle-free administration research.

Co-Delivery & Multivalent Research Systems

• Dual-Cargo Encapsulation: Engineering lipid carriers to simultaneously encapsulate hydrophilic antigens (in the core) and hydrophobic adjuvants (in the bilayer) to ensure synchronized delivery to antigen-presenting cells.
• Multivalent mRNA Formulation: Optimization of lipid composition to accommodate multiple mRNA sequences in a single particle without compromising encapsulation efficiency or particle stability.
• Ratio Optimization: Precise control of antigen-to-adjuvant ratios using microfluidic mixing to evaluate synergistic immunological effects in preclinical models.
• Interference Reduction: Lipid shell design to minimize charge-based interference between complex payloads.

Lymph Node Targeting & Biodistribution

• Size-Dependent Trafficking: Precise control of particle size (typically 20-100 nm) via microfluidics to maximize passive drainage into lymphatic vessels for effective immune activation.
• Surface Charge Modulation: Utilization of anionic or neutral lipids to reduce local retention at the injection site and facilitate transport to draining lymph nodes.
• Ligand-Modified Lipids: Conjugation of specific ligands (e.g., Mannose, Galactose) to the lipid surface to enhance receptor-mediated uptake by dendritic cells or macrophages.
• PEG-Shedding Kinetics: Design of PEG-lipids with tunable lipid anchor lengths to control the rate of PEG shedding, balancing circulation time with cellular uptake efficiency.

Vaccine Formulation and Synthesis from R&D to Scale-Up

BOC Sciences offers a seamless, end-to-end CDMO workflow ranging from the custom synthesis of high-purity lipids and adjuvants to downstream formulation development. Our integrated capabilities ensure precise quality control and batch consistency from initial microfluidic screening through to preclinical scale-up.

Custom Lipid & Adjuvant Synthesis

• Synthesis of ionizable lipids with tunable pKa values for RNA delivery research.
• Manufacturing of high-purity excipients (cholesterol, DSPC, PEG-lipids) suitable for preclinical studies.
• Production of molecular adjuvants (CpG-lipids, STING agonists) with verified purity.
• Chemical modification of natural lipids to enhance stability parameters.

Formulation Development & Screening

• Microfluidic screening to identify optimal lipid-to-antigen (N/P) ratios.
• Optimization of particle size (typically 60-100 nm) and polydispersity index (PDI).
• Buffer exchange and cryoprotectant screening (Sucrose, Trehalose) for lyophilization studies.
• Process development for sterile filtration and aseptic handling.

Preclinical Bioassay Support

• In Vitro Potency: Reporter assays (Luciferase, GFP) to measure antigen expression efficiency in cell lines.
• Cellular Uptake: Flow cytometry analysis of particle internalization by dendritic cells and macrophages.
• Adjuvant Activity: Measuring cytokine markers (TNF-α, IL-6, IFN-γ) in PBMC cultures.
• Endotoxin Testing: LAL assays to ensure formulations meet preclinical safety standards.

Analytical Characterization

• Physical: DLS (Size/PDI), Zeta Potential, Cryo-TEM (Morphology/Lamellarity).
• Chemical: Encapsulation efficiency (RiboGreen/Picogreen), lipid composition quantification (HPLC-CAD).
• Stability: RNA integrity analysis (Capillary Electrophoresis) and thermal stability assessments.
• Purity: Impurity profiling of lipids and degradation products via LC-MS.

Scale-Up & Manufacturing

• Tech transfer from bench-scale (mL) to pilot-scale (L) using continuous flow mixing technologies.
• Production of batches suitable for GLP toxicology studies.
• Sterile fill-finish into vials.
• Cold-chain management and stability testing (-80°C to +25°C).

Your Trusted Partner for Lipid and Vaccine Delivery Solutions

• Structure-Activity Relationship (SAR) Design: We apply SAR analysis to engineer ionizable lipids with precise pKa values (typically 6.0–7.0), optimizing the balance between stability in circulation and efficient endosomal escape upon cellular uptake.
• Adjuvant Conjugation Capabilities: Our team specializes in chemically conjugating molecular adjuvants, such as TLR7/8 agonists or MPLA analogs, directly to lipid backbones to ensure synchronized antigen-adjuvant delivery to immune cells.
• Diverse Lipid Library: Clients access a proprietary library featuring biodegradable lipids with varied ester-linkage positions and head-group chemistries, facilitating the screening of formulations for specific tissue tropism and clearance profiles.
• Integrated Quality Control: We synthesize high-purity lipid excipients in-house and perform downstream formulation, ensuring full batch traceability and consistency without reliance on third-party raw material suppliers.
• Payload Versatility: Our microfluidic platform is optimized to encapsulate diverse payloads, from standard mRNA to large self-amplifying RNA (saRNA) constructs and hydrophobic peptide antigens, with high encapsulation efficiency.
• Advanced Characterization: We utilize Cryo-TEM for morphological verification and HPLC-CAD for precise lipid quantification, providing comprehensive data packages that validate particle integrity and composition for preclinical filings.
• High-Throughput Prototyping: Utilizing automated microfluidic mixing systems, we generate formulation variants at the microliter scale (100 µL – 1 mL) to rapidly identify optimal N/P ratios before scaling up.

End-to-End Formulation Development for Your Project

We employ a systematic, Quality-by-Design (QbD) approach to vaccine formulation, designed to de-risk development early. Our roadmap guides projects from antigen assessment and microfluidic prototyping to process optimization, ensuring a smooth transition from benchtop feasibility to stable, GLP-ready manufacturing.

Antigen Assessment & Requirements

We begin by analyzing the antigen's physicochemical profile, including molecular weight and hydrophobicity. We then define critical success criteria, such as target administration routes and required stability profiles, to guide the subsequent formulation strategy.

Carrier Design & Component Selection

Based on the antigen profile, we select the optimal lipid carrier architecture (LNP, Liposome, or Hybrid). This involves integrating specific immunostimulants or targeting ligands to strictly define the mechanism of action for the intended research model.

Microfluidic Prototyping

Utilizing precision microfluidic mixing technologies, we rapidly generate diverse formulation variants at the microliter scale. This high-throughput approach allows for the efficient screening of encapsulation efficiency (>90%) and particle uniformity while conserving valuable antigen material.

In Vitro Screening

We systematically evaluate candidate formulations in relevant cell lines to assess transfection efficiency and cytokine induction. This rigorous screening process identifies high-potential candidates that demonstrate the optimal balance of biological potency and cellular viability.

Process Optimization & Stability Testing

We refine critical process parameters (CPPs), such as flow rate ratios and mixing speeds. Concurrently, we develop specific storage buffers or lyophilization cycles to maximize the long-term physical and chemical stability of the formulation.

Scale-Up & GLP Batch Production

We implement continuous flow manufacturing to linearly scale processes from milliliters to liters. This ensures the production of highly characterized, sterile-filtered batches suitable for use in regulated preclinical toxicology and immunogenicity studies.

Antigen-Specific Delivery Research Applications

mRNA & Self-Amplifying RNA (saRNA) Antigens

Challenge Solved: Nuclease Protection & Endosomal Escape.

Mechanism: Naked RNA is rapidly degraded by extracellular nucleases and cannot penetrate cell membranes. Ionizable LNPs encapsulate the RNA payload to protect the phosphodiester backbone from enzymatic hydrolysis. Furthermore, the pH-sensitive lipid component facilitates endosomal membrane disruption, enabling the efficient release of the RNA transcript into the cytoplasm for translation.

Recombinant Protein & Peptide Subunits

Challenge Solved: Cross-Presentation & Depot Effect.

Mechanism: Soluble proteins are often cleared rapidly and fail to access the MHC Class I pathway required for CD8+ T-cell responses. Cationic liposomes promote electrostatic adsorption of antigens, creating a depot at the injection site for prolonged exposure. Additionally, pH-sensitive liposomes facilitate cytosolic delivery, allowing exogenous proteins to be processed and cross-presented to cytotoxic T cells.

Polysaccharide & Glycoconjugate Antigens

Challenge Solved: Multivalent Display & B-Cell Activation.

Mechanism: Polysaccharides often induce weak, T-cell-independent immune responses. Lipid carriers serve as a scaffold to display polysaccharide antigens in a high-density, multivalent array that mimics the surface of bacteria. This structural organization enhances B-cell receptor clustering and activation, potentially improving the magnitude of the humoral immune response in research models.

Hydrophobic & Membrane-Bound Antigens

Challenge Solved: Solubility & Conformation Preservation.

Mechanism: Many viral envelope proteins or tumor-associated antigens are hydrophobic and aggregate in aqueous solution, losing their immunogenic conformation. These antigens can be reconstituted into the lipid bilayer of liposomes (forming virosomes or proteoliposomes). This mimics the native membrane environment, preserving the antigen's quaternary structure and neutralizing epitopes for optimal antibody recognition.

Frequently Asked Questions

Still have questions?

Contact Us

• How do you address mRNA stability in research formulations?

  We utilize lyophilization (freeze-drying) technology combined with cryoprotectant screening (e.g., sucrose/trehalose ratios). This research aims to develop formulations that remain stable at refrigerated temperatures, reducing reliance on ultra-cold storage during transport.

• Can you incorporate adjuvants into the LNP structure?

  Yes. We can chemically conjugate adjuvants to the lipid backbone or physically encapsulate hydrophobic adjuvants within the lipid core. This allows researchers to study the effects of co-delivering the antigen and the immunostimulant to the same cell.

• What is the function of helper lipids in your formulations?

  Helper lipids (typically phospholipids like DSPC or DOPE) are structural components that influence the phase transition temperature and membrane fluidity. In research contexts, they are selected to facilitate endosomal escape by promoting fusion with the endosomal membrane.

• Do you offer formulation services for self-amplifying RNA (saRNA)?

  Yes. saRNA constructs are larger than conventional mRNA. We have optimized processing parameters (mixing speeds, flow ratios) to encapsulate these larger payloads while maintaining particle integrity for research applications.

• What documentation is provided with the formulations?

  We provide detailed data reports including particle size analysis, encapsulation efficiency, and lipid composition verification. While our services are for research and preclinical use, the data packages are designed to support internal development milestones and grant applications.

• Are your ionizable lipids designed for biodegradability?

  Yes. Minimizing tissue accumulation is critical for safety. We prioritize the design of ionizable lipids containing biodegradable ester linkages within their hydrophobic tails. This structural feature promotes rapid enzymatic hydrolysis and clearance from the body following payload delivery, significantly reducing the potential for accumulation-related toxicity in preclinical models.

Case Studies and Success Stories

Publications

This section showcases academic publications from international research teams using BOC Sciences' products and services, highlighting our industry impact in lipid supply and R&D.

• An advanced TALSPEAK concept for separating minor actinides. Part 2. Flowsheet test with actinide-spiked simulant. Solvent Extraction and Ion Exchange 35.6 (2017): 396-407. DOI: 10.1080/07366299.2017.1368945.
• Development and validation of rapid and simultaneous method for determination of 12 hair-growth compounds in adulterated products by UHPLC–MS/MS. Forensic science international 284 (2018): 129-135. PMID: 29408720 DOI: 10.1016/j.forsciint.2017.12.042.
• Cuban Policosanol (Raydel®) Exerts Higher Antioxidant and Anti-Glycation Activities than Chinese Policosanol (BOC Sciences) in Reconstituted High-Density Lipoproteins: In Vivo Anti-Inflammatory Activities in Zebrafish and Its Embryos. Pharmaceuticals 17.4 (2024): 406. DOI: 10.3390/ph17040406.
• Hopanoids, like sterols, modulate dynamics, compaction, phase segregation and permeability of membranes. Biochimica et Biophysica Acta (BBA)-Biomembranes (2019): 183060. DOI: 10.1016/j.bbamem.2019.183060.
• The long-chain monounsaturated cetoleic acid improves the efficiency of the n-3 fatty acid metabolic pathway in Atlantic salmon and human HepG2 cells. Br J Nutr. 2019; 122(7): 755-768. DOI: 10.1017/S0007114519001478.

Client Testimonials

Industry Distribution of Vaccine Delivery Clients

"For our neoantigen research project, speed was critical. BOC Sciences provided characterized LNPs within the requested timeline, allowing us to proceed with our animal testing schedule without delay. The lipid quality was consistent."

— Dr. Elena Rossi, Principal Investigator (Italy)

"We encountered aggregation issues with our mucosal vaccine prototype. The formulation team at BOC Sciences optimized the surface properties, resulting in a stable suspension suitable for nebulization studies in our preclinical model."

— Prof. Kenji Yamamoto, Research Lead (Japan)

"Sourcing both high-purity lipids and custom adjuvant synthesis from a single provider simplified our material acquisition process. BOC Sciences has been a reliable partner for our preclinical development program."

— Dr. Mark Stevens, Senior Scientist (USA)

"Their assistance with lyophilization development was valuable. We now have a stable candidate for our distribution studies, which addresses a key logistical challenge in our research proposal."

— Dr. Sarah O'Connell, Project Lead (UK)

"BOC Sciences helped us scale our process from small-scale screening to liter-scale batches. The particle size distribution remained consistent, and the encapsulation efficiency met our research criteria."

— Mr. David Chen, Process Engineer (Singapore)

"We required a custom lipid-conjugated molecule for a mechanism-of-action study. BOC Sciences delivered the compound with the necessary purity, enhancing the reliability of our experimental data."

— Dr. Rebecca Hall, Research Scientist (Australia)